This market research report segments the global hospital infection therapeutics market by drug class (antibacterial, antiviral, and antifungal), by type of infections (urinary tract infections, respiratory tract infections, bloodstream infections, surgical site infections, and gastrointestinal infections), and by geography (APAC, EMEA, and the Americas). Leading vendors analyzed in this market study are Allergan, Bayer, GlaxoSmithKline, Merck, and Pfizer.
Technavio’s market research analysts estimate the global hospital infection therapeutics market to grow at a CAGR of more than 3% between 2015 and 2019. Hospital-acquired infections or nosocomial infections are a result of inadequate infection control programs in crowded hospital settings, increased medical procedures and surgeries, and decreased immunity of hospitalized patients. The Americas is the major revenue contributor to the hospital infection therapeutics market accounting for 43% of the total market share. Much of this region’s growth comes from the availability of better healthcare facilities and reimbursement policies.
The new market research report from Technavio provides a breakdown and analysis of the hospital infection therapeutics segments by technology.
“Increased exposure to microbes in hospital settings has led to widespread of infections and other diseases. Cardiac renal, and gastrointestinal disorders and cesarean section for childbirthare some of the most frequently performed surgeries. Surgeries increase the duration of hospital stay, thus augmenting the risk of contracting infections. Consequently, the hospitals and healthcare institutions have launched a number of infection control programs to control the spread of infections,” says Imran Mushtaq, Lead Analyst, Healthcare, Technavio Research.
Urinary tract infections are the most common form of nosocomial infections, affecting both non-catheterized and catheterized patients. The increasing usage of combination antibiotics for the treatment of such infections is expected to drive market growth during the forecast period.
The leading vendors in the global hospital infection therapeutics market are Allergan, Bayer, GlaxoSmithKline, Merck, and Pfizer. This market is expected to grow gradually during the forecast period owing to the augmented number of infection control programs and increased awareness about the diseases. The vendors manufacturing and marketing hospital infection therapeutics that can effectively treat and cure various life-threatening diseases are expected to gain a competitive edge over their peers.
A more detailed analysis is available in the Technavio report, Global Hospital Infection Therapeutics Market 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other related Reports:
- Global Hospital-acquired Disease Testing Market 2015-2019
- Global Infection Prevention and Control Market 2014-2018
Further Reading:
